Eastern Canadian Colorectal Cancer Consensus Conference 2017

about

Eastern Canadian Colorectal Cancer Consensus Conference 2017

Item

http://www.wikidata.org/entity/Q58783221

description

article

@en

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@en

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@nl

type

Item

label

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@en

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@nl

prefLabel

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@en

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@nl

P1476

Eastern Canadian Colorectal Cancer Consensus Conference 2017

@en

P2093

A Hyde

http://www.w3.org/2001/XMLSchema#string

A Jeyakumar

http://www.w3.org/2001/XMLSchema#string

A MacMillan

http://www.w3.org/2001/XMLSchema#string

A Muinuddin

http://www.w3.org/2001/XMLSchema#string

A Tate

http://www.w3.org/2001/XMLSchema#string

B Colwell

http://www.w3.org/2001/XMLSchema#string

C Booth

http://www.w3.org/2001/XMLSchema#string

C H Ahmad

http://www.w3.org/2001/XMLSchema#string

C Marginean

http://www.w3.org/2001/XMLSchema#string

D Armstrong

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer

Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma

Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability

Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X

Microsatellite instability in colorectal cancer

Colorectal Cancer Biomarkers: Where Are We Now?

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.

P304

262-274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.4083

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Dominick Bossé

P577

2018-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30111967

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

6092057

http://www.w3.org/2001/XMLSchema#string